Pauline Merrill to Treatment Outcome
This is a "connection" page, showing publications Pauline Merrill has written about Treatment Outcome.
Connection Strength
0.317
-
Suprachoroidal CLS-TA with and without Systemic Corticosteroid and/or Steroid-Sparing Therapy: A Post-Hoc Analysis of the Phase 3 PEACHTREE Clinical Trial. Ocul Immunol Inflamm. 2023 Oct; 31(8):1579-1586.
Score: 0.101
-
Efficacy of Adalimumab in Non-Infectious Uveitis Across Different Etiologies: A Post Hoc Analysis of the VISUAL I and VISUAL II Trials. Ocul Immunol Inflamm. 2021 Nov 17; 29(7-8):1569-1575.
Score: 0.093
-
Suprachoroidal triamcinolone acetonide versus rescue therapies for the treatment of uveitic macular oedema: A post hoc analysis of PEACHTREE. Clin Exp Ophthalmol. 2022 01; 50(1):23-30.
Score: 0.026
-
Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA). Br J Ophthalmol. 2022 08; 106(8):1139-1144.
Score: 0.024
-
Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology. 2021 06; 128(6):899-909.
Score: 0.024
-
Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA). Ophthalmology. 2016 11; 123(11):2413-2423.
Score: 0.018
-
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016 Sep 17; 388(10050):1183-92.
Score: 0.018
-
Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. Ocul Immunol Inflamm. 2012 Apr; 20(2):104-12.
Score: 0.013